7699
document
Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients . The efficacy and toxicity of once-daily ( od ) versus twice-daily ( bd ) dosing of vancomycin was compared in 121 hospitalized patients . Eighteen patients were then withdrawn from the study . Clinical and bacteriological responses were evaluated in all patients ( n = 103 ) . Nephrotoxicity was assessed in patients who did not receive nephrotoxic agents ( n = 76 ) . Ototoxicity was assessed in patients who completed two audiograms and were not receiving ototoxic agents ( n = 63 ) . No significant difference was found between the two groups for favourable clinical response : 47/51 ( 92.1 % ) and 49/52 ( 94.2 % ) in the od and bd groups , respectively . In 34 patients vancomycin was the only effective antibiotic . Fifteen of 18 ( 83.3 % ) evaluated episodes in the od and 12/16 ( 75.0 % ) evaluated episodes in the bd group showed a favourable bacteriological response . There were no significant differences between the od and bd groups for all adverse events . Nephrotoxicity developed in 4/37 ( 10.8 % ) and 3/39 ( 7.7 % ) patients , respectively . Hearing loss developed in 1/31 ( 3.2 % ) and 5/32 ( 15.6 % ) . Phlebitis occurred in 7/51 ( 13.7 % ) and 12/52 ( 23.0 % ) . Red man syndrome occurred in 7/51 ( 13.7 % ) and 5/52 ( 9.6 % ) in od and bd groups , respectively . The efficacy and safety profile of od administration of vancomycin is similar to that of the customary , but less convenient , bd administration .
7700
Intervention_Pharmacological
vancomycin
7701
Intervention_Pharmacological
vancomycin
7702
Intervention_Pharmacological
vancomycin
7703
Intervention_Pharmacological
vancomycin
7704
Outcome_Physical
Nephrotoxicity
7705
Outcome_Physical
Ototoxicity
7706
Outcome_Other
only effective antibiotic
7707
Outcome_Other
favourable bacteriological response
7708
Outcome_Adverse-effects
all adverse events
7709
Outcome_Adverse-effects
Nephrotoxicity
7710
Outcome_Adverse-effects
Hearing loss
7711
Outcome_Adverse-effects
Phlebitis
7712
Outcome_Physical
Red man syndrome
7713
Outcome_Other
efficacy and safety profile
7714
Participant_Condition
infections in hospitalized patients
7715
Participant_Sample-size
121
7716
Participant_Condition
hospitalized
7717
Participant_Sample-size
Eighteen
7718
Participant_Sample-size
103